GH Research price target lowered to $40 from $45 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on GH Research to $40 from $45 and keeps a Buy rating on the shares. The analyst believes GH should be able to address FDA’s concerns but admits the hold has potential to delay or alter the clinical development path of GH001. The firm pushed back the initial expected year of launch for GH001 to 2027 from 2026.